Enovis Corp Stock Price, News & Analysis

Enovis (NYSE: ENOV) has announced the appointment of Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald, who brings over 35 years of medical device industry experience, will succeed Matt Trerotola, who is retiring. McDonald will also join the Enovis Board of Directors after the 2025 Annual Meeting on May 21.

McDonald previously served as CEO of LivaNova, where he improved growth, profitability, and shareholder value. His experience includes leadership roles at Danaher, Zimmer, and Johnson & Johnson's Ethicon unit. The company has reiterated its Q1 2025 guidance with expected revenues of $555-563 million and adjusted EBITDA of $97-100 million.

Sharon Wienbar, currently Lead Independent Director, will become Board Chair following Trerotola's retirement. The company will address questions about the transition during its Q1 2025 earnings call on May 8, 2025.

Enovis (NYSE: ENOV) will showcase its expanding foot and ankle solutions portfolio at the ACFAS Annual Scientific Conference in Phoenix from March 27-30, 2025. The company will highlight several innovative products, including the new Tarsoplasty Percutaneous Lapidus Correction System for bunionectomy procedures.

The exhibition will feature advanced solutions such as OssiGraft Prime viable bone matrix allografts, Aircast AirSelect Elite pneumatic walking boot, Velocity+ proximal extension cuff, and Regeneration OL1000 bone growth stimulator. New research comparing the Arsenal Foot Plating System's screw angulation will also be presented.

The company will host two special events: 'Phoenix Rising: Foot & Ankle Edition' on March 28 and a Flatfoot/MIS Techniques Workshop on March 26.

Enovis (NYSE: ENOV) has announced its management team's participation in three upcoming investor conferences in March and April 2025. The schedule includes:

• Canaccord Genuity Musculoskeletal Conference: CFO Ben Berry and Recon Group President Louie Vogt will join a fireside chat on March 10th at 10:00 a.m. PT
• 37th Annual Roth Conference: Recon Group President Louie Vogt will participate in a fireside chat on March 17th at 8:30 a.m. PT
• 24th Annual Needham Healthcare Conference: CFO Ben Berry will engage in a fireside chat on April 8th at 1:30 p.m. ET

Live audio webcasts and replays will be accessible through the Investors tab under Events and Presentations on the company's website.

Enovis (NYSE: ENOV) reported strong Q4 2024 results with net sales of $561 million, up 23% year-over-year and 6% on comparable sales basis. The company's Reconstructive segment showed impressive growth of 59% reported (10% comparable), while Prevention & Recovery grew 2% reported (3% comparable).

However, Enovis reported a significant Q4 net loss from continuing operations of $704 million, primarily due to a $645 million non-cash goodwill impairment charge. Q4 adjusted EBITDA reached $113 million (20% of sales), showing 210 basis points improvement year-over-year.

For full-year 2024, net sales grew to $2.1 billion, up 23% reported and 6% comparable. The company provided 2025 guidance expecting revenue of $2.19-2.22 billion with 6-6.5% organic growth and adjusted EBITDA of $405-415 million. CEO Matt Trerotola announced his planned retirement, with a succession process underway.

Enovis (NYSE: ENOV) announced that CEO Matt Trerotola plans to retire upon the appointment of his successor. The Board of Directors is actively working with an executive search firm to identify a new growth-oriented MedTech leader.

Following the appointment, Trerotola will serve as an Executive Advisor to the Company and his successor for one year to ensure a smooth leadership transition. The Board emphasized their commitment to maintaining the company's strategy of growth through innovative medical technology solutions and continuing the EGX business system culture.

The leadership transition will be addressed during Enovis' fourth quarter and full-year 2024 financial results conference call.

Enovis (NYSE: ENOV) has announced it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2024 financial results on Wednesday, February 26th, 2025 at 8:30 a.m. Eastern Time. The company will release its earnings press release earlier that morning.

A presentation related to the call will be accessible from the 'Investors' section of Enovis' website. Investors can participate by dialing (833) 685-0901 for U.S. callers and (412) 317-5715 for International callers. A replay of the call will be available on the company's website later that day.

Enovis (NYSE: ENOV) has announced a leadership transition in its International Surgical Business. Davide Visentin will succeed Dr. Benjamin Reinmann as President, effective March 1, 2025. Visentin brings over 20 years of healthcare experience, most recently serving as VP and General Manager at BD's Integrated Diagnostic Solutions, where he managed 700+ employees across 50 countries.

Prior to BD, Visentin held leadership positions at Stryker's Joint Replacement and Robotic Division and Johnson & Johnson Depuy Synthes. He holds a Computer Science degree from the University of Milan and will primarily operate from Villanova, Italy, and Bettlach, Switzerland.

The company highlighted its progress in building its International Surgical Business, emphasizing its commitment to market share growth and innovation in global orthopedics.

Enovis (NYSE: ENOV), a medical technology growth company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will present on Monday, January 13th, 2025, at 9:45 a.m. PST (12:45 p.m. EST).

Investors and interested parties can access the live audio webcast, presentation slides, and event replay through the Events and Presentations section of the company's website at www.enovis.com.

Enovis (NYSE: ENOV) has announced its management team's participation in two upcoming investor conferences. At the Jefferies London Healthcare Conference, Chair and CEO Matt Trerotola and CFO Ben Berry will join a fireside chat on November 20th at 12:00 p.m. GMT. Subsequently, CFO Ben Berry will participate in the Evercore 7th Annual HealthCONx Conference on December 4th at 10:50 a.m. ET.

Both events will be available via live audio webcasts and replays on the company's website under the Investors tab. Enovis is a medical technology growth company focused on developing clinically differentiated solutions for better patient outcomes and workflow transformation in orthopedics and beyond.